Viewing Opinion | StockChase
Teva Pharmaceutical (TEVA-N) opinion on 2017-04-20

Last Price Recorded: 13.3300 on 2017-11-21

ON STOCKCHASE SINCE Dec 2000

biotechnology/pharmaceutical
PARTIAL BUY

Lorne Zeiler
Teva Pharmaceutical was $30.760 at time of opinion
Owned : Unknown

A cheap, but troubled stock. It is the leading generics pharmaceutical provider globally. They overextended themselves a while ago, in trying to get into specialty Pharma areas, which has been a bit of a problem. Expected to generate a little over $5 in earnings next year, a 6X earnings multiple. The Pharma sector as a whole tends to be 3X, so this is very, very cheap. The dividend is over 4%. The negative is that the management team is in flux. Also, the Department of Justice now has an inquiry into price fixing potential by the generic providers. The balance sheet is incredibly levered at 4.8X EBITDA. This is worth taking a half position and then growing that out. If things start to normalize and they get the earnings they are projecting, it should really start seeing 20%, 30%, 40% growth from here.

UNKNOWN

All opinions for TEVA-N (234)

45 BUY
4 BUY on WEAKNESS
43 COMMENT
39 DON'T BUY
13 HOLD
2 PARTIAL BUY
26 PAST TOP PICK
8 SELL
3 STRONG BUY
44 TOP PICK
1 VAGUE
4 WAIT
2 WATCH
View All

More experts covering TEVA-N

SAVE
Add TEVA-N to Watch List

All opinions for TEVA-N (234)

45 BUY
4 BUY on WEAKNESS
43 COMMENT
39 DON'T BUY
13 HOLD
2 PARTIAL BUY
26 PAST TOP PICK
8 SELL
3 STRONG BUY
44 TOP PICK
1 VAGUE
4 WAIT
2 WATCH
View All

More experts covering TEVA-N

SAVE
Add TEVA-N to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company